Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Report from the 5th cardiovascular outcome trial (CVOT) summit

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th–25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th–30th, 2020 ( https://www.cvot.org).

          Related collections

          Most cited references 18

          • Record: found
          • Abstract: found
          • Article: not found

          Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

          The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

            Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

              Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.
                Bookmark

                Author and article information

                Contributors
                oliver.schnell@lrz.uni-muenchen.de
                Eberhard.Standl@lrz.uni-muenchen.de
                francescxaviercos@gmail.com
                h.j.lambers.heerspink@umcg.nl
                tamibar@inter.net.il
                lalic.nm@gmail.com
                michael.nauck@rub.de
                antonio.ceriello@hotmail.it
                Journal
                Cardiovasc Diabetol
                Cardiovasc Diabetol
                Cardiovascular Diabetology
                BioMed Central (London )
                1475-2840
                17 April 2020
                17 April 2020
                2020
                : 19
                Affiliations
                [1 ]Forschergruppe Diabetese e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764 Munich, Germany
                [2 ]Sant Marti de Provençals Primary Care Centres, Barcelona, Spain
                [3 ]GRID grid.4830.f, ISNI 0000 0004 0407 1981, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, , University of Groningen, ; Groningen, The Netherlands
                [4 ]GRID grid.415508.d, ISNI 0000 0001 1964 6010, George Institute for Global Health, , George Institute, ; Camperdown, Sydney, NSW Australia
                [5 ]GRID grid.6451.6, ISNI 0000000121102151, Clalit Health Services and Technion Faculty of Medicine, ; 3 Zivoni Street, Haifa, Israel
                [6 ]Faculty of Medicine, University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Dr Subotica 13, Belgrade, 11000 Serbia
                [7 ]GRID grid.416438.c, Diabetes Division, , St. Josef-Hospital (Ruhr University), ; Bochum, Germany
                [8 ]GRID grid.420421.1, ISNI 0000 0004 1784 7240, Department of Cardiovascular and Metabolic Diseases, , IRCCS MultiMedica, ; Via Milanese 300, 20099 Sesto San Giovanni (MI), Italy
                Article
                1022
                10.1186/s12933-020-01022-7
                7165375
                32303223
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                Categories
                Commentary
                Custom metadata
                © The Author(s) 2020

                Comments

                Comment on this article